All In Biotech

Drug Trial Radar · NCT00861705

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

454

Actual

Start

Jul 21, 2009

Primary completion

Aug 1, 2014

Study completion Sep 2, 2025

Sponsor

Sponsor type
NIH
First posted
Mar 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Conditions

  • Male Breast Carcinoma
  • Stage IIA Breast Cancer AJCC v6 and v7
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage IIIA Breast Cancer AJCC v7
  • Triple-Negative Breast Carcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • CarboplatinDrug

    Given IV

  • CyclophosphamideDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).Time frame: At the time of definitive surgical removal, up to 28 weeks
  2. Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).Time frame: At the time of definitive surgical removal, up to 28 weeks

Locations

448 sites in 1 country. Site status is shown where the registry gives one.

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • NEA Baptist Memorial Hospital

    Jonesboro, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • El Camino Hospital

    Mountain View, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Wilma Chan Highland Hospital

    Oakland, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Tumor Institute

    Oakland, California

  • Hematology and Oncology Associates-Oakland

    Oakland, California

  • Tom K Lee Inc

    Oakland, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • Desert Regional Medical Center

    Palm Springs, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Valley Care Health System - Pleasanton

    Pleasanton, California

  • Valley Medical Oncology Consultants

    Pleasanton, California

  • Salinas Valley Memorial

    Salinas, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Doctors Medical Center- JC Robinson Regional Cancer Center

    San Pablo, California

  • Breastlink Medical Group Inc

    Santa Ana, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • The Medical Center of Aurora

    Aurora, Colorado

  • Boulder Community Foothills Hospital

    Boulder, Colorado

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • AdventHealth Porter

    Denver, Colorado

  • Presbyterian - Saint Lukes Medical Center - Health One

    Denver, Colorado

  • Saint Joseph Hospital - Cancer Centers of Colorado

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

Showing 40 of 448 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.